Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Analysts Are Warming to Virgin Galactic’s Future Plans

Analysts continue to pile on the Virgin Galactic bandwagon. Here’s why even more investment professionals will get excited about SPCE stock.  

The Historical Costco Premium Is Getting Downright Silly

Guggenheim analyst John Heinbockel believes Costco stock is expensive. He’s recommending investors don’t buy at current prices. Is he right?

To Buy Levi Strauss or Not to Buy, That Is the Question Leading Up to Earnings

It’s been a little more than 18 months since Levi Strauss went public at $17 a share. Now trading below its IPO price, is Levi stock a buy?  

Can Renewable Energy Deliver for General Electric Shareholders?

General Electric was selected to supply 190 turbines for a British wind farm. Is this the tonic that can cure the GE stock woes? Probably not.

Marathon Oil Shareholders Haven’t Fared Well Since Its Downstream Spinoff

It will soon be a decade since Marathon Oil spun off its downstream business. How have owners of MRO stock made out as a result of its move?

The News Keeps Getting Better and Better for Alibaba 

Alibaba’s other businesses are moving to profitability. Investors who own BABA stock have every right to be excited about the future.  

Did Seattle’s Move on the Hourly Wage Make Lyft Uninvestable?

Seattle passed a minimum hourly wage of $16.39 for Lyft drivers. If you own Lyft stock get used to this kind of thing happening worldwide. 

Martha Stewart Reminds Investors Why Canopy Growth Remains a Cannabis Leader

The launch of Martha Stewart’s hemp-derived wellness supplements is a reminder that CGC stock has a lot more going for it than meets the eye.

How to Decide if Inovio Is a Buy After Its 28% Correction

Inovio Pharmaceuticals fell 28% after the FDA put a partial clinical hold on vaccine trial. Should you buy INO stock on the dip?  

7 Food Stocks to Buy That Will Fatten Your Bank Account

Beyond Meat has the best performance year to date of food stocks with a market cap of $2 billion or more. Here are six others to buy.